Search for a trial

An interventional, prospective IVD device study for the testing of DNA extracted from tumor tissue biopsy samples in a first line setting from patients diagnosed with metastatic Colorectal Cancer (mCRC) to determine the KRAS G12C mutation status as part of the inclusion criteria into the Amgen Phase III clinical trial (Protocol No 20210081) to demonstrate clinical performance of the therascreen® KRAS RGQ PCR Kit.

To utilize the therascreen KRAS RGQ PCR Kit, as a screening test in Amgen*s Phase 3 Clinical Study Protocol 20210081, in order to identify patients with mCRC KRAS G12C mutation positive tumors to be enrolled in the drug clinical trial. Results of…

FITFOOD

This project aims to improve physical performance in older patients, by offering a personalized combined nutritional intervention with a physical activity training program. The intervention starts at hospita! admittance, and is continued after…

HAKA trial 10 years follow-up

Primary: investigate the (cost-)effectiveness of replacing RFU after THA and TKA at 10 years by COD by comparing the complications and clinical visits between patients with COD versus RFU at 10 years after THA and TKA. Secondary: investigate the…

HAKA trial 1 year follow-up

To investigate the (cost-)effectiveness of COD compared to RFU at 1 year, up to 2 years after THA and TKA.